Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population

BACKGROUND: Lenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficacy of lenvatinib monotherapy. Patient-derived xenografts (PDX) are established b...

Descripción completa

Detalles Bibliográficos
Autores principales: Karalis, John D., Yoon, Lynn Y., Hammer, Suntrea T. G., Hong, Changjin, Zhu, Min, Nassour, Ibrahim, Ju, Michelle R., Xiao, Shu, Castro-Dubon, Esther C., Agrawal, Deepak, Suarez, Jorge, Reznik, Scott I., Mansour, John C., Polanco, Patricio M., Yopp, Adam C., Zeh, Herbert J., Hwang, Tae Hyun, Zhu, Hao, Porembka, Matthew R., Wang, Sam C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900296/
https://www.ncbi.nlm.nih.gov/pubmed/35255940
http://dx.doi.org/10.1186/s12967-022-03317-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900296/
https://www.ncbi.nlm.nih.gov/pubmed/35255940
http://dx.doi.org/10.1186/s12967-022-03317-7

Ejemplares similares